Study of how risankizumab moves through the body in healthy adults
Treatments studied
This trial studies how the drug risankizumab moves through your body after being given through a vein or under the skin. It helps doctors understand the best way to give the medicine to patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh between 88 and 220 pounds (40 to 100 kg).
- Your body mass index (BMI) is between 18 and 32. (You can use an online calculator to check.)
- You are generally healthy, with no major medical issues.
- You have not taken any medicines that block IL-12 or IL-23 (like Stelara or Skyrizi) in the past year.
- You avoid strenuous exercise you're not used to for a week before and during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
This study looks at pregnancy outcomes in people who took risankizumab during pregnancy (or shortly before getting pregnant). It compares them with pregnancies exposed to similar biologic medicines, to better understand risks and what to expect.
Hear when a new Healthy Volunteer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.